X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2027) 2027
Patent (38) 38
Publication (23) 23
Book Chapter (17) 17
Book / eBook (7) 7
Conference Proceeding (6) 6
Web Resource (4) 4
Magazine Article (2) 2
Newspaper Article (2) 2
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1068) 1068
cardiac & cardiovascular systems (784) 784
female (620) 620
male (617) 617
middle aged (557) 557
aged (507) 507
mortality (383) 383
treatment outcome (295) 295
risk factors (256) 256
prognosis (250) 250
clinical trials (240) 240
abridged index medicus (232) 232
medicine, general & internal (226) 226
heart attack (217) 217
heart attacks (208) 208
acute myocardial-infarction (195) 195
peripheral vascular disease (192) 192
drug therapy (189) 189
myocardial infarction - drug therapy (189) 189
cardiovascular (179) 179
care and treatment (177) 177
angioplasty (169) 169
thrombolytic therapy (164) 164
electrocardiography (163) 163
cardiology (162) 162
follow-up studies (162) 162
heart failure (159) 159
myocardial infarction - mortality (158) 158
cardiac patients (155) 155
united states (150) 150
coronary heart disease (147) 147
acute coronary syndromes (146) 146
therapy (146) 146
risk (141) 141
myocardial infarction (139) 139
time factors (136) 136
cardiovascular disease (133) 133
outcomes (131) 131
randomized controlled trials as topic (125) 125
unstable angina (121) 121
trial (120) 120
myocardial infarction - therapy (118) 118
double-blind method (117) 117
survival analysis (117) 117
patient outcomes (113) 113
analysis (111) 111
prospective studies (111) 111
management (108) 108
platelet aggregation inhibitors - therapeutic use (103) 103
angioplasty, balloon, coronary (101) 101
coronary artery bypass (101) 101
survival (101) 101
health aspects (100) 100
research (100) 100
proportional hazards models (98) 98
coronary angiography (97) 97
risk assessment (97) 97
cardiology and cardiovascular medicine (96) 96
medical research (96) 96
platelet glycoprotein gpiib-iiia complex - antagonists & inhibitors (96) 96
acute disease (95) 95
prevention (93) 93
myocardial infarction - complications (92) 92
coronary disease - therapy (88) 88
myocardial-infarction (87) 87
fibrinolytic agents - therapeutic use (85) 85
disease (84) 84
adult (83) 83
evaluation (83) 83
hematology (82) 82
stroke (80) 80
thrombolysis (79) 79
survival rate (78) 78
coronary disease - mortality (77) 77
recurrence (75) 75
hospitalization (74) 74
multivariate analysis (74) 74
retrospective studies (74) 74
streptokinase (73) 73
surgery (73) 73
tissue plasminogen activator - therapeutic use (72) 72
studies (71) 71
transluminal angioplasty (71) 71
usage (70) 70
aspirin (68) 68
cardiovascular diseases (68) 68
drug therapy, combination (67) 67
patients (67) 67
reperfusion (67) 67
heparin (66) 66
myocardial infarction - physiopathology (66) 66
aged, 80 and over (65) 65
anticoagulants (65) 65
clinical trials as topic (65) 65
coronary vessels (65) 65
internal medicine (65) 65
predictive value of tests (63) 63
clinical outcomes (62) 62
anticoagulants - therapeutic use (60) 60
myocardial infarction - diagnosis (60) 60
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2121) 2121
French (13) 13
German (6) 6
Portuguese (3) 3
Norwegian (1) 1
Polish (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2015, Volume 372, Issue 25, pp. 2387 - 2397
In this trial, patients with an acute coronary syndrome within the previous 10 days were randomly assigned to simvastatin plus either ezetimibe or placebo. At... 
no | CHOLESTEROL ABSORPTION | CARDIAC OUTCOMES | MEDICINE, GENERAL & INTERNAL | MYOCARDIAL-INFARCTION | EFFICACY | CARDIOVASCULAR OUTCOMES | CLINICAL-TRIALS | SIMVASTATIN | PRIMARY PREVENTION | IMPROVE-IT | ATORVASTATIN | Simvastatin - therapeutic use | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Azetidines - adverse effects | Ezetimibe | Kaplan-Meier Estimate | Male | Anticholesteremic Agents - adverse effects | Acute Coronary Syndrome - drug therapy | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Azetidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Triglycerides - blood | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Cholesterol, LDL - blood | Female | Aged | Drug Therapy, Combination | Usage | Simvastatin | Analysis | Practice guidelines (Medicine) | Dosage and administration | Drug therapy, Combination | Acute coronary syndrome | Drug therapy | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | Angina | Cholesterol | Intestine | Gallbladder | Acute coronary syndromes | Cardiovascular diseases | Statins | Pharmaceuticals | Cancer | Life Sciences | Human health and pathology | Cardiology and cardiovascular system
Journal Article
2007, 3rd ed., ISBN 9780781770125, 1871
Updated throughout by renowned international authorities, Dr. Topol's best-selling text provides a comprehensive, contemporary view of every area of... 
Cardiology | Cardiovascular Diseases
eBook
The New England journal of medicine, ISSN 1533-4406, 2009, Volume 360, Issue 21, pp. 2176 - 2190
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 373, Issue 3, pp. 232 - 242
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2011, Volume 365, Issue 10, pp. 883 - 891
In this trial, 14,264 patients with atrial fibrillation were randomly assigned to receive either rivaroxaban or warfarin. In a per-protocol, as-treated... 
NON-INFERIORITY | ENOXAPARIN | MEDICINE, GENERAL & INTERNAL | DABIGATRAN | STROKE PREVENTION | PHARMACOKINETICS | EFFICACY | ANTITHROMBOTIC THERAPY | PHARMACODYNAMICS | THROMBOPROPHYLAXIS | ANTICOAGULATION | Thiophenes - therapeutic use | Thiophenes - adverse effects | Humans | Middle Aged | Warfarin - adverse effects | Male | Thiophenes - administration & dosage | Warfarin - administration & dosage | Warfarin - therapeutic use | Rivaroxaban | Aged, 80 and over | Female | Stroke - epidemiology | Embolism - epidemiology | Morpholines - adverse effects | Morpholines - therapeutic use | Stroke - prevention & control | Embolism - prevention & control | Double-Blind Method | Administration, Oral | Atrial Fibrillation - drug therapy | Morpholines - administration & dosage | Atrial Fibrillation - complications | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | Intention to Treat Analysis | Aged | Hemorrhage - chemically induced | Stroke (Disease) | Warfarin | Atrial fibrillation | Patient outcomes | Dosage and administration | Drug therapy | Comparative analysis | Risk factors | Fees & charges | Cardiac arrhythmia | Stroke | Heart attacks | Research & development--R&D | Embolisms | Equity | Equity stake | Hemorrhage | Bleeding | Embolism | Studies | Prevention | Fibrillation | Motivation | Ischemia | Thromboembolism | Drug dosages | Pharmaceuticals | Anticoagulants | Morpholines | Life Sciences | Thiophenes | Atrial Fibrillation
Journal Article
Lancet neurology, ISSN 1474-4422, 2012, Volume 11, Issue 4, pp. 315 - 322
Journal Article
Journal Article